About
Laurence Reid, Ph.D., is a biotech executive and company builder best known for serving as CEO of Decibel Therapeutics through its 2023 acquisition by Regeneron and earlier as CEO of Warp Drive Bio until its merger with Revolution Medicines. He previously held senior business leadership roles at Alnylam, Ensemble, and Millennium, and later served as entrepreneur in residence at Third Rock Ventures. He now focuses on board and advisory work across biotech companies including Shift Bioscience, KalVista Pharmaceuticals, Metagenomi, and Broken String Biosciences.
Areas of interest
longevitybiotechgenetic medicinesgene therapygenome editingdrug discoveryAI in biotechcell rejuvenationrare disease therapeuticsboard governance